Publication | Open Access
OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
45
Citations
0
References
2021
Year
Advanced NsclcMedicineOa03.03 Datopotamab DeruxtecanPathologyImmune Checkpoint InhibitorTrop2 AdcCancer TreatmentOncologyRadiation OncologyCancer Research
No additional data available for this publication yet. Check back later!